Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan for Migraine Prevention
NCT04574713Phase 2Completed
- Sponsor
- St. Olavs University Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, triple-blind trial of candesartan in migraine (3 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Change in number of migraine days per 4 weeks at 12 weeks. Started Apr 2021; status: completed.
02
Drugs
candesartan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04574713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04574713.